

Cizzle Biotechnology Holdings plc

("Cizzle Biotechnology", or the "Company")

Notice of Annual General Meeting

Cizzle Biotechnology, the UK based diagnostics developer, announces that the notice of Annual General Meeting ("AGM"), has been sent to shareholders and is available for viewing on the Company's website at <https://cizzlebiotechnology.com>.

The AGM will be held at 11.00 a.m. on 24 June 2024 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale
George Payne

+44(0) 20 3328 5656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test to facilitate the early detection of lung cancer based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant has been shown to be highly correlated with early-stage lung cancer. The Company's proprietary technology results from the work of Professor Coverley and colleagues at the University of York.

For more information please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.